These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35921500)

  • 1. Differential requirement of Hippo cascade during CTNNB1 or AXIN1 mutation-driven hepatocarcinogenesis.
    Liang B; Wang H; Qiao Y; Wang X; Qian M; Song X; Zhou Y; Zhang Y; Shang R; Che L; Chen Y; Huang Z; Wu H; Monga SP; Zeng Y; Calvisi DF; Chen X; Chen X
    Hepatology; 2023 Jun; 77(6):1929-1942. PubMed ID: 35921500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Axis inhibition protein 1 (Axin1) Deletion-Induced Hepatocarcinogenesis Requires Intact β-Catenin but Not Notch Cascade in Mice.
    Qiao Y; Wang J; Karagoz E; Liang B; Song X; Shang R; Evert K; Xu M; Che L; Evert M; Calvisi DF; Tao J; Wang B; Monga SP; Chen X
    Hepatology; 2019 Dec; 70(6):2003-2017. PubMed ID: 30737831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.
    Liang B; Zhou Y; Qian M; Xu M; Wang J; Zhang Y; Song X; Wang H; Lin S; Ren C; Monga SP; Wang B; Evert M; Chen Y; Chen X; Huang Z; Calvisi DF; Chen X
    J Hepatol; 2021 Jul; 75(1):120-131. PubMed ID: 33577921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TAZ is indispensable for c-MYC-induced hepatocarcinogenesis.
    Wang H; Zhang S; Zhang Y; Jia J; Wang J; Liu X; Zhang J; Song X; Ribback S; Cigliano A; Evert M; Liang B; Wu H; Calvisi DF; Zeng Y; Chen X
    J Hepatol; 2022 Jan; 76(1):123-134. PubMed ID: 34464659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unraveling the impact of AXIN1 mutations on HCC development: Insights from CRISPR/Cas9 repaired AXIN1-mutant liver cancer cell lines.
    Zhang R; Li S; Schippers K; Eimers B; Niu J; Hornung BVH; van den Hout MCGN; van Ijcken WFJ; Peppelenbosch MP; Smits R
    PLoS One; 2024; 19(6):e0304607. PubMed ID: 38848383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct and Overlapping Roles of Hippo Effectors YAP and TAZ During Human and Mouse Hepatocarcinogenesis.
    Wang H; Wang J; Zhang S; Jia J; Liu X; Zhang J; Wang P; Song X; Che L; Liu K; Ribback S; Cigliano A; Evert M; Wu H; Calvisi DF; Zeng Y; Chen X
    Cell Mol Gastroenterol Hepatol; 2021; 11(4):1095-1117. PubMed ID: 33232824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RSK2 inactivation cooperates with AXIN1 inactivation or β-catenin activation to promote hepatocarcinogenesis.
    Schaeffer S; Gupta B; Calatayud AL; Calderaro J; Caruso S; Hirsch TZ; Pelletier L; Zucman-Rossi J; Rebouissou S
    J Hepatol; 2023 Sep; 79(3):704-716. PubMed ID: 37201672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. β-Catenin signaling in hepatocellular carcinoma.
    Xu C; Xu Z; Zhang Y; Evert M; Calvisi DF; Chen X
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.
    Weiler SME; Lutz T; Bissinger M; Sticht C; Knaub M; Gretz N; Schirmacher P; Breuhahn K
    Cancer Lett; 2020 Mar; 473():164-175. PubMed ID: 31904487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
    Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
    Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interacting network of Hippo, Wnt/β-catenin and Notch signaling represses liver tumor formation.
    Kim W; Khan SK; Yang Y
    BMB Rep; 2017 Jan; 50(1):1-2. PubMed ID: 27881216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conditional disruption of Axin1 leads to development of liver tumors in mice.
    Feng GJ; Cotta W; Wei XQ; Poetz O; Evans R; Jardé T; Reed K; Meniel V; Williams GT; Clarke AR; Dale TC
    Gastroenterology; 2012 Dec; 143(6):1650-9. PubMed ID: 22960659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hippo signaling interactions with Wnt/β-catenin and Notch signaling repress liver tumorigenesis.
    Kim W; Khan SK; Gvozdenovic-Jeremic J; Kim Y; Dahlman J; Kim H; Park O; Ishitani T; Jho EH; Gao B; Yang Y
    J Clin Invest; 2017 Jan; 127(1):137-152. PubMed ID: 27869648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEIS2C and MEIS2D promote tumor progression via Wnt/β-catenin and hippo/YAP signaling in hepatocellular carcinoma.
    Guan L; Li T; Ai N; Wang W; He B; Bai Y; Yu Z; Li M; Dong S; Zhu Q; Ding XX; Zhang S; Li M; Tang G; Xia X; Zhao J; Lin S; Yao S; Zhang L; Chen G; Liu FE; Li X; Zhang H
    J Exp Clin Cancer Res; 2019 Oct; 38(1):417. PubMed ID: 31623651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
    Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
    Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hippo Cascade Controls Lineage Commitment of Liver Tumors in Mice and Humans.
    Zhang S; Wang J; Wang H; Fan L; Fan B; Zeng B; Tao J; Li X; Che L; Cigliano A; Ribback S; Dombrowski F; Chen B; Cong W; Wei L; Calvisi DF; Chen X
    Am J Pathol; 2018 Apr; 188(4):995-1006. PubMed ID: 29378174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas.
    Zucman-Rossi J; Benhamouche S; Godard C; Boyault S; Grimber G; Balabaud C; Cunha AS; Bioulac-Sage P; Perret C
    Oncogene; 2007 Feb; 26(5):774-80. PubMed ID: 16964294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of AXIN1 and AXIN2 as targets of tankyrase inhibition in hepatocellular carcinoma cell lines.
    Wang W; Liu P; Lavrijsen M; Li S; Zhang R; Li S; van de Geer WS; van de Werken HJG; Peppelenbosch MP; Smits R
    Sci Rep; 2021 Apr; 11(1):7470. PubMed ID: 33811251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.